Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2015-11-01
2018-12-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Secondary objective is to assess gastrointestinal tolerance and acute bowel changes.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fiber Effects on Glycemic Index
NCT02831738
Post-prandial Glycemic Response to Fiber in Healthy Adults
NCT03252704
Effect of Three Fibres on Glycaemic and Insulinaemic Responses in Healthy Adult Volunteers
NCT02701270
Study to Assess Safety and Effect of a Prebiotic Fiber Meal Replacement Shake in Individuals With Type 2 Diabetes
NCT05110703
Assessment of the Glycemic Responses to Nutritional Products (v2.0)
NCT05308147
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A planned sample size of 40 will be enrolled into the study. This study will require one initial screening visit and 4 weekly study visits. This study will take approximately 4 weeks per subject to complete.
The initial screening visit will provide subject with the informed consent document and determine subject eligibility through anthropometric measurements, vital signs, fasting blood glucose test (finger prick), and completion of a survey relate to general eating, health, and exercise habits.
If willing and eligible to participate, subjects will be invited to participate in the study for 4 study days. Subjects will be instructed to maintain their usual diet pattern and physical activity throughout study duration. A dinner meal will be provided the day before the study visit to control the second meal effect from the food and beverage intake of the night before the study visit.
Subject will arrive at the center in a fasted state for at least 10 hours, well hydrated and rested. Each study visit will require blood draws throughout the visit. After evaluation of subject's health status (via anthropometric, vital sign and blood glucose measurements and in-person interview), a Licensed health Care Professional will place a catheter in subject's arm for the purpose of multiple blood sample collections and take the initial blood draw in the fasting state. Subjects will be randomized to receive a placebo or treatment beverage based on randomized treatment sequences for 4 study visits. The sequences of receiving the beverage treatments at each visit will be randomly assigned to one of sequences.
Each study visit will involve with blood samples collection at time points 0 (fasting), 0.5, 1, 2, 3 hour (h) for assessment of change in plasma glucose and insulin concentrations.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active Treatment 1
8g Polydextrose
8 g Polydextrose
8g of Polydextrose
Active Treatment 2
12 g Polydextrose
12 g Polydextrose
12 g of Polydextrose
Active Treatment 3
16 g Polydextrose
16 g Polydextrose
16 g of Polydextrose
Placebo
0 g Polydextrose
Placebo
0 g of Polydextrose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
8 g Polydextrose
8g of Polydextrose
12 g Polydextrose
12 g of Polydextrose
16 g Polydextrose
16 g of Polydextrose
Placebo
0 g of Polydextrose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject has BMI between 20.0 and 32.0 kg/m2 at screening visit
* Fasting blood sugar less than 126 mg/dL
* Subject is willing to maintain a stable body weight and to follow his/her regular diet and physical activity patterns throughout the study period.
* Subject is willing to refrain from vigorous physical activity and consumption of alcoholic and/or caffeinated beverages 24 h prior to each test day
* Subject does not smoke or has abstained from smoking for at least 2 years
* No clinical evidence of cardiovascular, metabolic, respiratory, renal, gastrointestinal or hepatic disease
* Not taking any medications or dietary supplements that would interfere with outcomes of the study.
* Subject typically consumes a low fiber diet that correlates with the average fiber intake of typical western diet.
Exclusion Criteria
* Men and women with known or suspected food intolerance, allergies or hypersensitivity to the study materials or closely related compounds
* Men and women known to have/diagnosed with diabetes mellitus
* Men and women with a fasting blood glucose concentration ≥126 mg/dL
* Average blood pressure \> 140 mmHg/90 mmHg during screening visit
* Men and women with documented vascular disease, e.g., heart failure, myocardial infarction, stroke, angina, related surgeries
* Men and women with cancer other than non-melanoma skin cancer in previous 5 years
* Men and women who are taking medication or dietary supplements that may interfere with the outcomes of the study. Subjects may choose to go off dietary supplements (requires 30 days washout)
* Men and women who have donated blood within 3 months of the screening visit and blood donors/participants for whom participation in this study will result in having donated more than 1500 milliliters of blood in the previous 12 months
* Substance (alcohol or drug) abuse within the last 2 years
* Excessive coffee and tea consumption (\> 4 cups/day)
* Unstable weight: gained or lost weight +/- 5 lbs in previous 3 months
* Women who are known to be pregnant or who are intending to become pregnant over the course of the study and women who are lactating.
* Men and women whom investigator is uncertain about subject's capability or willingness to comply with protocol requirements
* Special or atypical diet - eg. vegan, gluten free, excessively high or low energy/fiber
* Women who are taking unstable dose and brand of hormonal contraceptives and/or stable dose and brand less than 6 months.
* Men and women who do excessive exercise regularly or athlete
20 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Clinical Nutrition Research Center, Illinois Institute of Technology
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Britt Britt Burton-Freeman, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Illinois Institute of Technology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Nutrition Research Center
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB2015-104
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.